US Merck Joins Race to Take Medivation

(c) AJP/Shutterstock
(c) AJP/Shutterstock

US-based Merck & Co is the latest company to consider buying US biopharmaceuticals firm Medivation. Citing people familiar with the matter, news agency Reuters reported that Merck & Co is one of five drugs firms that have submitted their interest in the California-based company. The others are Sanofi, Pfizer, Celgene and Gilead Sciences.

Medivation has already rejected two offers from Sanofi, the most recent in July for $58/share in cash plus $3/share in the form of a contingent value right relating to sales for Talazoparib, Medivation’s potential breast cancer treatment. Last month, Medivation agreed to open its books after the French drugmaker said it would drop efforts to replace the company’s board of directors.

For Merck, Medivation would complement its existing cancer portfolio which includes Keytruda, a leading immuno-oncology treatment that is expected to achieve sales of around $5 billion by 2020. In its second-quarter earnings call this month, Medivation reported an 11% year-on-year rise in sales of its blockbuster prostate cancer drug Xtandi, affirming the company’s expectations of more than 50% growth in revenue this year. It also cited positive late-stage trial data for Talazoparib.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.